( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , 

 ISSN 2394-3211

Impact Factor: 6.222

 ICV - 79.57



Vinod K.*, Shraddha D. and Sonia J.


Background: Healthcare cost, including the cost of therapy for treatment of cardiac diseases are a growing burden on public domain, the standard care on which public money is spent during hospitalization is a matter of concern. Benefits of UFH in Acute Coronary Syndrome (ACS) have been well-established. However, now extensive variety of newer anticoagulants like low molecular weight heparin, direct thrombin inhibitor and selective factor Xa Inhibitor are available for clinical use. The objective of the study was to evaluate the cost of enoxaparin versus unfractionated heparin in Myocardial infarction. Methods and material: This prospective observational study included patients admitted in ICU and HDU which were divided into three groups. Group 1 received treatment with low molecular weight heparin (LMWH) (n=30), group 2 received treatment with unfractionated heparin (UFH) (n=24) and group 3 received treatment with both LMWH and UFH (n=30). Demographic data & direct cost of pharmacological treatment was collected for each patient. Finally, the total cost for all drugs received by the patients during six months period was calculated. Results: 84 out of 196 patients were included with the primary diagnosis of acute myocardial infarction over the interval of six months. A total of 319 drugs was prescribed in 84 patients and mean number of drugs prescribed per patient were 10±1.9 (range 8-15) in Group-I, 10±1.5 (range 8- 12) in Group-II and 13±2.6 (range 10-19) in Group-III. The average cost of anticoagulants was more in Group III (Rs. 7461 ± 2604.19) as compared group I (Rs.3936 ± 1655.46) and group II (Rs. 409 ± 347.37). Conclusion: For treating acute myocardial infarction in hospitalized patients unfractionated heparin can be initiated and then switching to enoxaparin appears to be cost saving and more beneficial, although cost implications depends on local revascularization practice. For treating acute myocardial infarction in hospitalized patients, enoxaparin is an economical attractive option. The higher acquisition cost of enoxaparin is compensated by reduction in catheterization, revascularization procedures, decreased hospital stay resulting in overall cost-saving.

Keywords: ACS, ICU and HDU.

[Full Text Article]




    JANUARY issue has been successfully launched on 1 JANUARY 2023.

  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 January 2023 Issue has been Published, Kindly check it on

  • EJPMR New Impact Factor

    Its our Pleasure to Inform you that EJPMR Impact Factor has been increased from  5.804 to 6.222, due to high quality Publication at International Level

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database